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1604Objective: The study objective was to examine the incidence, risk factors, and mortality rate of acute
exacerbation of interstitial lung diseases in patients with lung cancer undergoing pulmonary resection in a
large-scale multi-institutional cohort.
Methods: We retrospectively analyzed 1763 patients with non–small cell lung cancer who had undergone
pulmonary resection and presented with a clinical diagnosis of interstitial lung diseases between January 2000
and December 2009 at 61 hospitals in Japan. The incidence and outcomes of acute exacerbation within 30 days
from the operation were investigated. Univariate and multivariate logistic regression analyses were used to
identify independent risk factors of acute exacerbation.
Results: Acute exacerbation occurred in 164 patients (9.3%; 95% confidence interval, 8.0-10.8), with a
mortality rate of 43.9%, and was the top cause of 30-day mortality (71.7%). The following 7 independent
risk factors of acute exacerbation were identified: surgical procedures, male sex, history of exacerbation,
preoperative steroid use, serum sialylated carbohydrate antigen KL-6 levels, usual interstitial pneumonia
appearance on computed tomography scan, and reduced percent predicted vital capacity. Surgical procedures
showed the strongest association with acute exacerbation (using wedge resection as the reference, lobectomy
or segmentectomy: odds ratio, 3.83; 95% confidence interval, 1.94-7.57; bi-lobectomy or pneumonectomy:
odds ratio, 5.70; 95% confidence interval, 2.38-13.7; P< .001). The effect of perioperative prophylactics,
such as steroids and sivelestat, was not confirmed in this study.
Conclusions: Pulmonary resection for patients with lung cancer with interstitial lung diseases may provoke
acute exacerbation at a substantially high rate and has high associated mortality. Surgical procedures
that proved to be a risk factor for acute exacerbation should be chosen cautiously for these high-risk patients.
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Interstitial lung diseases (ILDs) are associated with an
increased risk of lung cancer.1,2 Therapeutic modalities
for patients with lung cancer with ILDs should be
selected carefully because interventions may provoke
exacerbation of ILDs.3,4 Pulmonary resection has been
shown to be associated with high postoperative morbidity
and mortality in these patients. Postoperative acute
exacerbation (AE) of interstitial pneumonia is one such
possible comorbidity and is associated with mortality rates
between 33.3% and 100%.5-8 In addition to treatment-
related morbidity and mortality, the prognosis of ILDs
itself—particularly in patients with idiopathic pulmonary
fibrosis (IPF)—can be a life-limiting factor. Several retro-
spective studies suggest a median survival time of patients
with IPF from 2 to 3 years after diagnosis.9-13 Whethergery c May 2014
Abbreviations and Acronyms
AE ¼ acute exacerbation
ALI ¼ acute lung injury
ARDS ¼ acute respiratory distress syndrome
CI ¼ confidence interval
CRP ¼ C-reactive protein
CT ¼ computed tomography
DLCO ¼ diffusing capacity for carbon monoxide
FEV1 ¼ forced expiratory volume in 1 second
FEV1% ¼ percent forced expiratory volume in 1
second
ILD ¼ interstitial lung disease
IPF ¼ idiopathic pulmonary fibrosis
OR ¼ odds ratio
PaCO2 ¼ partial pressure of carbon dioxide
%DLCO ¼ percent predicted diffusing capacity for
carbon monoxide
%VC ¼ percent vital capacity
UIP ¼ usual interstitial pneumonia
VC ¼ vital capacity
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Spulmonary resections are indicated for patients with lung
cancer with fibrosis remains a matter of debate.8,14-16
To determine the most appropriate treatment strategy, a
reliable assessment of the risks and benefits of the various
interventions is required. However, no cohort study of a suf-
ficiently large scale for this purpose has been conducted.
The purpose of this study was therefore to clarify the inci-
dence, risk factors, and outcomes of postoperative AE in pa-
tients with lung cancer with ILDs who had undergone
pulmonary resection. At the initiative of the Japanese Asso-
ciation for Chest Surgery, we have conducted a large-scale
multi-institutional retrospective cohort study to inform the
decision-making process for these patients.MATERIALS AND METHODS
Study Design and Patients
The design of the study was planned by Drs Sato, Teramukai, and Date
with assistance from the advisory board of the Japanese Association for
Chest Surgery and the Project Team for Diffuse Lung Diseases, organized
by the Japanese Ministry of Health, Labour and Welfare. The study proto-
col was approved by the institutional review boards of all participating hos-
pitals, including that of the Ethics Committee, Kyoto University Graduate
School and Faculty of Medicine (Approval Number: E-982).
The original data for analysis were obtained from patients with non–
small cell lung cancer who had undergone pulmonary resection and pre-
sented with a clinical diagnosis of ILD between January 2000 and
December 2009 at 64 institutions throughout Japan.
The primary end point for outcomes analysis was postoperative AE of
interstitial pneumonitis within 30 days after pulmonary resection. Medical
records of the patients were reviewed for age; sex; comorbidities, including
collagen and respiratory diseases; smoking history; blood work and phys-
iologic data, including white blood cells, C-reactive protein (CRP), lactate
dehydrogenase, KL-6 (sialylated carbohydrate antigen KL-6), carcinoem-
bryonic antigen, partial pressure of oxygen, partial pressure of carbonThe Journal of Thoracic and Cardioxide (PaCO2), vital capacity (VC), percent vital capacity (%VC), forced
expiratory volume in 1 second (FEV1), percent FEV1 (FEV1%), percent
predicted FEV1, diffusing capacity for carbon monoxide (DLCO), and
percent predicted DLCO (%DLCO); operation time; bleeding amount;
perioperative prophylactics, including steroids, sivelestat sodium hydrate,
ulinastatin, and combinations thereof; surgical procedures; tumor location;
pathologic diagnosis; and cancer pTNM stages based on the 6th edition of
the American Joint Committee on Cancer lung cancer staging.
Inclusion Criteria for Patients With Interstitial Lung
Diseases
Diagnoses of ILDs were confirmed on the basis of a combination of clin-
ical and radiologic findings according to the clinical criteria proposed by the
Japanese Respiratory Society,17 which are consistent with the guidelines of
the American Thoracic Society in 2011.12 The cases were categorized into
2 groups according to their radiologic appearance on computed tomography
(CT) scan: (1) usual interstitial pneumonia (UIP) pattern: characterized by the
presence of basal-dominant reticular opacities and predominantly basal and
subpleural distribution of honeycomb lesions, with multiple equal-sized
cystic lesions of 2 to 10 mm diameter with a thick wall; and (2) non-UIP
pattern: characterized by the presence of basal-predominant ground glass
opacities and infiltrative shadows inconsistent with UIP patterns.
Definition of Postoperative Acute Exacerbation
AE caused by pulmonary resection was defined on the basis of criteria
proposed by the American Thoracic Society Guidelines12 and Yoshimura
and colleagues.18 These criteria were (1) onset within 30 days after pulmo-
nary resection, (2) intensified dyspnea, (3) increase in the interstitial
shadow on chest radiograph and chest CT scan, (4) decrease in arterial ox-
ygen tension of more than 10 mm Hg under similar conditions, (5) no ev-
idence of pulmonary infection, and (6) exclusion of alternative causes, such
as cardiac failure, pulmonary embolism, or other identifiable causes of lung
injury. Exacerbations occurring from 31 days onward were defined as
chronic exacerbations.
Patient Characteristics
Data were initially obtained from 41,742 consecutive patients with lung
cancer who had undergone pulmonary resections in 64 institutions; 2418 of
these patients presented with ILDs. Because of poor quality of data, 404
cases from 3 institutions were excluded from the study. In addition, 135
cases were excluded because their fibrotic changes were pathologically
confirmed, but there were no apparent fibrotic changes detected on CT
scans. After reviewing all data for eligibility, completeness, and consis-
tency, 116 more cases were excluded, leaving 1763 cases with ILDs
deemed eligible for final analysis in this study.
The demographics of the cohort used in this study are shown in Table 1.
The majority of patients were men (90.4%) and ex- or current smokers
(93.8%). History of AE of interstitial pneumonia treated before the index
pulmonary resection was observed in 1.1% of patients. Approximately
6.2% of patients had been treated preoperatively with steroids and other
immunosuppressant drugs, 4.2% of patients had induction chemotherapy,
and 1.8% of patients had radiation therapy. UIP diagnoses were made in
73.7% of patients by CT scan, and 45.7% of patients were confirmed path-
ologically with resected specimens as having UIP. Squamous cell carci-
noma was the most common type of lung cancer.
Statistical Analyses
Univariate logistic regression analysis was performed to preliminarily
evaluate the associations between the incidence of AE and the following
candidate patient characteristics: age, sex, body mass index, smoking his-
tory, Brinkman index, comorbidities (asthma, emphysema, and collagen
disease), neoadjuvant chemotherapy, neoadjuvant radiation therapy, white
blood cells, CRP, lactate dehydrogenase, KL-6, carcinoembryonic antigen,diovascular Surgery c Volume 147, Number 5 1605
TABLE 1. Patient characteristics
Characteristics
No. of
patients (%)
Median
(range)
Age, y 1763 71 (36-88)
Sex
Male/female 1593 (90.4)/170 (9.6)
BMI, kg/m2 1746 23.0 (13.7-37.0)
Smoking history
Never smoker 109 (6.2)
Ex-smoker 1006 (57.6)
Current smoker 632 (36.2)
Brinkman index 1742 1000 (0-5760)
Comorbidity
Asthma
/þ 1724 (98.1)/33 (1.9)
Emphysema
/þ 1167 (66.5)/589 (33.5)
Collagen disease
/þ 1654 (94.2)/102 (5.8)
History of AE*
/þ 1741 (98.9)/20 (1.1)
Preoperative
medication
for IP
None/steroids/
others
1638 (93.8)/103 (5.9)/6 (0.3)
Neoadjuvant
chemotherapy
/þ 1686 (95.8)/73 (4.2)
Neoadjuvant
radiation
/þ 1728 (98.2)/32 (1.8)
Radiologic
diagnosis
UIP/non-UIP
pattern
1300 (73.7)/463 (26.3)
Histology
Squamous cell
carcinoma
816 (46.9)
Adenocarcinoma 721 (41.4)
Large cell
carcinoma
64 (3.7)
Others 139 (8.0)
pTNM stage
1a 547 (31.6)
1b 481 (27.8)
2a 70 (4.0)
2b 241 (13.9)
3a 244 (14.1)
3b 114 (6.6)
4 34 (2.0)
Surgical procedure
Wedge resection 275 (15.7)
Segmentectomy 150 (8.5)
Lobectomy 1236 (70.4)
Bilobectomy 61 (3.5)
Pneumonectomy 33 (1.9)
(Continued)
TABLE 1. Continued
Characteristics
No. of
patients (%)
Median
(range)
Tumor location
Upper lobe 670 (39.2)
Middle lobe 77 (4.5)
Lower lobe 958 (56.0)
Multiple 5 (0.3)
VATS
/þ 964 (54.7)/798 (45.3)
Node dissection
0/1/2 331 (17.7)/339 (19.3)/1104 (63.0)
The pTNM staging was based on the 6th edition of the American Joint Committee on
Cancer lung cancer staging. AE,Acute exacerbation; BMI, body mass index; IP, inter-
stitial pneumonia; UIP, usual interstitial pneumonia; VATS, video-assisted thoraco-
scopic surgery. *History of treated AE before pulmonary resection.
General Thoracic Surgery Sato et al
1606 The Journal of Thoracic and Cardiovascular Sur
G
T
Spartial pressure of oxygen, PaCO2, VC, %VC, FEV1, FEV1%, %FEV1,
DLCO,%DLCO, radiologic findings, pathologic findings, history of AE,
preoperative steroid use, pTNM stage, operation time, bleeding amount,
transfusion, surgical procedures, tumor location, video-assisted thoraco-
scopic surgery, and node dissection.
Risk factors for inclusion in the multivariate analysis were selected on
the basis of the results of the univariate analyses, statistical independence,
and clinical significance for preoperative patient evaluation of AE risk.
Surgical procedures were categorized into 3 groups on the basis of the
results of multivariate analyses that adjusted for the other covariates.
These groups were wedge resection, lobectomy and segmentectomy, and
bilobectomy and pneumonectomy.Multivariate logistic regression analysis
using backward elimination was used to identify independent risk factors
for AE and to estimate the respective odds ratios (ORs) and their 95%
confidence intervals (CIs) of the various risk factors. All reported P values
were 2-sided. The cutoff value for %VC was set at 80%, which is the
widely accepted clinical criteria for restrictive change of pulmonary
fibrosis, and is correlated to disease progression and patient survival.19
For KL-6, 1000 U/mL was determined as the cutoff value on the basis of
the results of a preliminary receiver operating characteristic analysis,
which showed 1040 U/mL to be the optimal cutoff value with a c-index
of 0.583. Data management and statistical analyses were conducted in
the Department of Clinical Trial Design and Management, Translational
Research Center, Kyoto University Hospital. All statistical analyses were
performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS
Incidence of Acute Exacerbation
Postoperative AE developed within 30 days after the
operation in approximately 9.3% of patients (95% CI,
8.0-10.8) who had undergone pulmonary resection. AE
developed within 10 days after operation in the majority
of the patients (64.6%), with postoperative day 4 showing
the highest frequency of AE. The mortality rate of each
postoperative day varied from 0% to 100%, and showed
no particular tendency or trend (Figure 1 and Table 2).
Risk Factor Analysis for Acute Exacerbation
Univariate and multivariate analyses were carried out to
identify possible risk factors for AE. The univariate analysis
identified sex, KL-6, PaCO2,%VC, FEV1.0%, DLCO, radio-
logic findings, history of AE, preoperative use of steroids,gery c May 2014
FIGURE 1. Histogram of AE incidence within 30 days after pulmonary resection (n¼ 164). Black columns represent patient death (72 cases, 43.9%), and
white columns represent patient survival (92 cases, 56.1%). AE developed in the majority of the patients (64.6%) within 10 days after operation, with post-
operative day 4 showing the highest frequency of AE. AE, Acute exacerbation.
TABLE 2. Incidence of acute exacerbation, its outcomes, and 30-day
mortality of patients undergoing pulmonary resection
Categories No. of patients (%) Median (range)
30-d mortality 46 (2.6)
30-d mortality by cause of death
AE 33 (71.7)
Infection 3 (6.5)
Pulmonary embolism 1 (2.1)
Others 9 (19.5)
AE
 1599 (90.7)
þ 164 (9.3)*
Days from operation to AE 7 (0-29)
Outcome of AE
Alive 92 (56.1)
Death 72 (43.9)
Days from AE to death 20 (1-82)
Side of AE
Operation side 22 (14.2)
Contralateral 39 (25.2)
Bilateral 94 (60.6)
AE,Acute exacerbation (occurring within 30 days after pulmonary resection). *9.3%;
95% CI, 8.0-10.8.
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(Table E1). VC and FEV1 were excluded as candidates
because these variables were highly correlated with %VC
(Spearman’s r¼ 0.796 and 0.603, respectively). Multivariate
analysis further identified the following risk factors for AE:
sex, KL-6,%VC, radiologic findings, history of AE, preop-
erative steroid use, and surgical procedures (Table 3).
The lobectomy/segmentectomy and the bilobectomy/
pneumonectomy groups were both more likely to develop
AE than the wedge resection group, with ORs of 3.83 and
5.70, respectively. AE was 3 times more likely to develop
in male patients than in female patients. Preoperative ste-
roid use, history of AE, UIP pattern on CT scans, elevated
levels of KL-6, and reduced%VC were identified as inde-
pendent risk factors for AE. Neoadjuvant treatment and
video-assisted thoracoscopic surgery showed no association
with AE in our study (Table E1).
Surgical Procedures and Acute Exacerbation Risk
Multivariate analysis of surgical procedures adjusting for
KL-6, preoperative steroid use, sex, CT findings,%VC, and
history of AE was carried out. The associated risk of AE
gradually increased according to resected lung volume.
By using the wedge resection group as the referent category,
the OR for AE in the segmentectomy group was 3.675
(95%CI, 1.586-8.519; P¼ .0024); the OR in the lobectomy
group was 3.861 (95% CI, 1.946-7.660; P<.001); the OR
in the bilobectomy group was 5.055 (95% CI, 1.871-
13.660; P ¼ .001); and the OR in the pneumonectomy
group was 6.953 (95% CI, 2.260-21.390; P<.001).The Journal of Thoracic and CarRisk Factor Analysis for Acute Exacerbation in
Patients With Usual Interstitial Pneumonia Patterns
on Computed Tomography Scan
Subgroup analyses were carried out for the patients with
UIP patterns on CT scans. To ensure only patients with UIP/
IPF were included in this subgroup analysis, we excluded
65 patients with collagen diseases; a total of 1235 cases
were analyzed. Sex, CRP, KL-6, %VC, FEV1, history ofdiovascular Surgery c Volume 147, Number 5 1607
TABLE 3. Results of multivariate logistic regression analyses of acute exacerbation in all patients and in the usual interstitial pneumonia subgroup
Factors
All patients (n ¼ 1763) UIP subgroup (n ¼ 1235)*
Patients (n) AE (%) OR 95% CI P value Patients (n) AE (%) OR 95% CI P value
Surgical procedures .0005y .0005y
Wedge resection 275 10 (3.6) 1.000 — — 202 10 (5.0) 1.000 — —
Lobectomy/segmentectomy 1386 138 (10.0) 3.83 1.941-7.567 .0001 955 100 (10.5) 2.91 1.453-5.847 .0026
Bilobectomy/pneumonectomy 94 15 (16.0) 5.7 2.381-13.66 .0001 70 14 (20.0) 5.96 2.413-14.74 .0001
N/A 8 1 (12.5) 8 1 (12.5)
KL-6 (U/mL)
<1000z 834 68 (8.2) 1.000 — — 571 56 (9.8) 1.000 — —
1000 209 34 (16.3) 2.14 1.344-3.394 .0013 151 27 (17.9) 2.02 1.199-3.408 .0083
N/A 720 62 (8.6) 513 42 (8.2)
Sex
Male 1593 158 (9.9) 1.000 — — 1138 123 (10.8) 1.000 — —
Female 170 6 (3.5) 0.3 0.126-0.688 .0047 97 2 (2.1) 0.18 0.043-0.737 .0172
%VC
<80 263 36 (13.7) 1.000 — — 191 30 (15.7) 1.000 — —
80 1478 126 (8.5) 0.63 0.417-0.959 .0308 1033 94 (9.1) 0.57 0.350-0.884 .0131
N/A 22 2 (9.1) 11 1 (9.1)
History of AE
 1741 158 (9.1) 1.000 — — 1223 120 (9.8) 1.000 — —
þ 20 6 (30.0) 3.24 1.063-9.897 .0387 10 5 (50.0) 7.67 1.997-29.42 .0030
N/A 2 0 (0.0) 2 0 (0.0)
Preoperative steroid use
 1651 144 (8.7) 1.000 — —
þ 103 20 (19.4) 2.46 1.356-4.454 .0031
N/A 9 0 (0.0)
CT findings
UIP pattern 1300 134 (10.3) 1.000 — —
Non-UIP pattern 463 30 (6.5) 0.59 0.386-0.900 .0143
AE, Acute exacerbation; CI, confidence interval; CT, computed tomography; N/A, not available; OR, odds ratio;%VC, percent vital capacity; UIP, usual interstitial pneumonia.
*Cases with collagen diseases were excluded (n¼ 65). yP value among 3 surgical procedure categories. zThe cutoff value of 1000 U/mL was determined on the basis of the result
of the receiver operating characteristic analysis.
TABLE 4. Use of prophylactics and acute exacerbation
Factors
No. of
patients (%) OR 95% CI
P
value
Prophylactics
 1216 (69) 1.000 — —
þ 544 (31) 1.047 0.724-1.513 .808
Steroid 194 (11.4) 0.862 0.491-1.514 .605
Sivelestat 115 (6.7) 1.397 0.752-2.596 .290
Sivelestat þ steroid 92 (5.4) 0.749 0.338-1.661 .477
Ulinastatin 69 (4.0) 2.488 1.266-4.887 .008
Sivelestat þ ulinastatin 5 (0.3) 1.302 0.109-15.49 .835
Steroid þ ulinastatin 11 (0.6) 0.000 N/A N/A
Sivelestat þ steroid þ
ulinastatin
4 (0.2) 1.035 0.089-12.03 .978
Adjusted for surgical procedures, KL-6, preoperative steroid use, sex, CT findings,%
VC, and history of AE. CI, Confidence interval; OR, odds ratio.
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identified as possible risk factors of AE in the univariate
analyses. Multivariate analysis using these factors identified
surgical procedures, history of AE, KL-6,%VC, and male
sex as independent risk factors (Table 3).
Prophylactics and Acute Exacerbation
During the perioperative period, 31% of the patients
were administered prophylactics. Steroids were the most
common drug for this purpose (11.4%), followed by sivele-
stat (6.7%) and a combination of steroid and sivelestat
(5.4%). The results of multivariate analyses adjusted with
the aforementioned AE risk factors (surgical procedures,
sex, KL-6, preoperative steroid use, %VC, radiologic
findings, and history of AE) are shown in Table 4. Drug
administration, whether given individually or in combina-
tions, did not show any positive effects in preventing AE.
Morbidity and Mortality of Pulmonary Resection
Outcomes involving the morbidity and mortality of pul-
monary resections are summarized in Table 2. The 30-day1608 The Journal of Thoracic and Cardiovascular Surmortality rate was 2.6%, and the most frequent cause of
death was AE. In patients with an AE, the mortality rate
was 43.9%. Days from AE to death varied from 1 to 82
days (median, 20 days).gery c May 2014
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AE of interstitial pneumonia is a rapidly progressive dis-
order often observed in patients with ILDs. Its clinical
course is specific and distinguishable from infectious pneu-
monia. The criteria for identifying AE of pulmonary fibrosis
include an unexplained rapid worsening of dyspnea,
severely impaired gas exchange, new radiographic diffuse
alveolar infiltrates, and the absence of alternate causes,
such as infectious pneumonia, pulmonary embolism, pneu-
mothorax, and heart failure.20 Thoracic surgery for patients
with ILDs, including open lung biopsy and bronchoalveolar
lavage, may trigger this decompensating acute respiratory
failure.6,21 The mortality rate of AE is reportedly high5-8
and has been shown to be the major cause of death for
patients with lung cancer after pulmonary resection in a
report cumulating more than 10,000 cases from the
Japanese Joint Committee for Lung Cancer Registration
and in the 2009 annual report of the Japanese Association
for Thoracic Surgery.22,23 In light of these circumstances,
identifying the possible risk factors for AE and enabling
the stratification of patients according to risk are relevant
for chest surgeons to reduce operation-related mortality
and improve the outcomes of pulmonary resection in pa-
tients with lung cancer. To address these issues, we focused
on patients with ILDs with lung cancer and found that the
incidence of AE was 0.4% in patients with non–small
cell lung cancer and 9.3% in similar patients with ILDs;
to the best of our knowledge, these are the first such figures
reported with high statistical reliability in a large-scale
multi-institutional study. These figures were comparable
to the incidences documented in past reports, including
those of the aforementioned studies,21-26 and indicate the
difficulties in the treatment of patients with lung cancer
with ILDs. The similarities observed in incidences have
important implications for further comparisons with other
anticancer therapies, such as chemotherapy and
radiotherapy, which have been shown to be associated
with this fatal complication at the rate of 20% to 42.9%.3,4
We identified 7 risk factors for AE: surgical procedures,
elevated KL-6, sex, reduced%VC, history of AE, preoper-
ative steroid use, and UIP pattern on CT scan. Surgical pro-
cedures showed the strongest association with the incidence
of AE. Anatomic resection would result in more serious
insult to patients’ lungs when compared with wedge resec-
tion, because the former requires longer operation time and
increased hilar vascular procedures and node dissection,
which may hinder the lymphatic flow. In addition to damage
caused by perioperative patient management (eg, fluid over-
load, 1-lung ventilation, positive pressure ventilation, and
high concentration oxygen exposure), the resection of
larger lung volume likely gives greater stress to the endothe-
lium, which may result in AE. Likewise, the effect of a
reduced vascular bed is substantial in patients with lowerThe Journal of Thoracic and Car%VC because their residual lung volume is relatively
small, which may result in a higher incidence of AE. These
speculations are supported by our findings that the risk of
AE gradually increased according to the volume of lung
removed (wedge resection< segmentectomy< lobectomy
< bilobectomy < pneumonectomy). The less-invasive
video-assisted thoracoscopic surgery procedures did not
reduce the risk of AE.
The possible effects of blood transfusions on AE also
were considered. We conducted a risk-adjusted evaluation
using transfusions and the other 7 covariates, which showed
a significant association between transfusion and AE (OR,
2.04; 95% CI, 1.22-3.40; P ¼ .006). However, transfusion
also was observed to be highly correlated to the operative
procedures, which may bring about possible effects of mul-
ticollinearity if included in the same model. Furthermore,
the need for transfusions and operation time are to a large
degree unpredictable before surgery, which reduces their
potential effectiveness for preoperative identification of pa-
tients at high risk of developing AE. However, general oper-
ation time and the risk of bleeding can be grouped within the
types of surgical procedures. The inclusion of surgical pro-
cedures in the regression models may therefore adjust for
operation time and transfusions.
There are limited data on the value of serum biomarkers
in patients with ILDs. Among the clinical laboratory vari-
ables, only KL-6 was identified as an independent risk fac-
tor for AE, where patients with KL-6 levels more than 1000
IU had an AE incidence twice that of patients with lower
levels. KL-6, a circulating glycoprotein expressed from
type 2 alveolar pneumocytes and bronchiolar epithelial
cells, has been established as an indicator of damage to
alveolar cells.27,28 Elevated KL-6 levels have been docu-
mented in patients who had developed acute lung injury
(ALI) or acute respiratory distress syndrome (ARDS), and
this relationship may be used to predict patient outcomes.
In interstitial pneumonia, KL-6 is an independent factor re-
flecting the degree of clinical disease activity, confirmed by
Ga-citrate scintigraphy and clinical course.27 Our observa-
tions in which KL-6 was identified as a risk factor have clin-
ical significance because the elevated level of serum KL-6
indicates increased alveolar-capillary permeability, which
can lead to diffuse alveolar damage—the initial and essen-
tial aspect of AE.
Our results indicated that men had 3 times the risk of
developing AE than women. An additional analysis showed
that smoking history and the Brinkman index were higher in
men than in women; however, the results did not show any
significant association between a smoking habit and AE
incidence. Ruffini and colleagues documented that ALI/
ARDS developed in male patients at approximately 4 times
the rate of female patients,24 so the male lung may be more
susceptible to the insult of surgical intervention.diovascular Surgery c Volume 147, Number 5 1609
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reliable indicators of fibrotic change,12,13,17 an analysis of
lung function (including FEV1, FEV1%, %DLCO, and
%VC) showed that only %VC had a significant and
independent association with AE incidence, which was
congruent with the results reported by Kushibe and
colleagues29 and Shintani and colleagues.30
Our analysis showed that preoperative steroid use and
history of AE were independent risk factors for AE, which
is consistent with clinical expectations. These findings
represent the first time that the statistical associations
between these factors have been documented.
The findings in which patients with UIP patterns in CT
scans had a higher risk of developing AE also are consistent
with clinical expectations, because honeycomb lesions have
been reported to be associated with IPF and act as a prog-
nostic factor.31-33 Our own data corroborate this, because
patients with distinct honeycomb lesions had a higher risk
of developing AE (OR, 1.800; 95% CI, 1.157-2.800;
P ¼ .009). Further evaluation of the relationship between
the extent and the prevalence of honeycomb lesions in CT
scans and AE is required, which we were unable to do in
our large retrospective cohort study.
There is no current consensus among the numerous
studies regarding the relationship between prophylactic
use and postoperative AE.5 Prophylactic steroids are a com-
mon agent with an anti-inflammatory and stabilizing effect
on alveolar cells. However, previous studies with compara-
tively large cohorts also have revealed no preventive effects
from the perioperative administration of steroids.16,25
Neutrophil elastase is known to cause endothelial cell
injury and increase epithelial permeability, thereby
playing an important role in ALI or ARDS. Sivelestat
sodium hydrate is a neutrophil elastase inhibitor, and
although its clinical efficacy has yet to be clearly
demonstrated,34 it is widely used for the treatment of ALI
in Japan. In our cohort, up to 216 patients (12%) had
been administered sivelestat in the perioperative period,
ostensibly for its prophylactic effects on AE. In our
retrospective study, these prophylactics showed no positive
effect on AE prevention. A randomized prospective
study on the effects of prophylactics, such as macrolides,
N-acetylcysteine, and pirfenidone, is required to gain a
clearer understanding of this relationship.
Study Limitations
This study has several limitations that should be consi-
dered in the interpretation of the results. First, this was a
retrospective cohort study, which may not necessarily
reflect the characteristics of the entire population with this
disease entity. Second, the primary inclusion criterion was
CT appearance of ILDs. Although radiologic diagnoses
were made by each individual institute following criteria
based on widely used guidelines,12,17 UIP diagnosis may1610 The Journal of Thoracic and Cardiovascular Survary among the institutes. We were unable to conduct a
centrally controlled review of this aspect of the diagnosis,
particularly of the extent and area of honeycomb lesion,
which are putative risk factors for the AE.CONCLUSIONS
In this study, we have clarified the incidence, risk factors,
and outcomes of postoperative AE in patients with lung
cancer with ILDs who had undergone pulmonary resection.
These results provide essential information for comparisons
with other anticancer therapies, such as chemotherapy and
radiotherapy. We identified 7 risk factors for AE onset.
By evaluating the presence and degree of the identified
risk factors before surgery, we can stratify patients and
identify those at high risk for pulmonary resection. Surgical
procedures were found to be the strongest risk factor and
may represent a crucial step in reducing the incidence of
this potentially fatal complication. The findings in this
study provide essential information to support fair and
objective decision-making by oncologists in the treatment
of this difficult entity.
The authors thank Kyosuke Kimura, Asakazu Ogasawara, and
Seiko Sakai for laborious efforts in the data management.References
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APPENDIX E1. PARTICIPATING CENTERS AND
INVESTIGATORS
NHO Hokkaido Cancer Center, Hokkaido (H. Adachi);
NHO Sendai Medical Center, Miyagi (T. Hasumi); Insti-
tute of Development Aging and Cancer Tohoku Univer-
sity, Miyagi (Y. Hoshikawa); Japanese Red Cross
Ishinomaki Hospital, Miyagi (S. Suzuki); Ohta Nishinou-
chi Hospital, Fukushima (Y. Matsumura); Nishi-Niigata
Chuo National Hospital, Niigata (T. Watanabe); Niigata
University, Niigata (H. Shinohara); Maebashi Red Cross
Hospital, Gunma (M. Kamiyoshihara); NHO Nishi-
Gunma Hospital, Gunma (O. Kawashima); Dokkyo
Medical University, Tochigi (M. Chida); Saitama Cardio-
vascular and Respiratory Center, Saitama (N. Takahashi);
Tokyo Medical University, Tokyo (N. Ikeda); Tokyo
Women’s Medical University, Tokyo (M. Kanzaki); Tokyo
Toranomon Hospital, Tokyo (A. Miyamoto); Juntendo
University School of Medicine, Tokyo (T. Matsunaga);
Tokyo Metropolitan Cancer and Infectious Disease Center
Komagome Hospital, Tokyo (H. Horio); Tokyo Medical
and Dental Hospital, Tokyo (K. Okubo); Toho University
Omori Medical Center, Tokyo (Y. Hata); The University
of Tokyo Graduate School of Medicine, Tokyo (J. Naka-
jima); Hachioji Medical Center of Tokyo Medical Univer-
sity, Tokyo (H. Miura); Kitasato University School of
Medicine, Kanagawa (Y. Satoh); Kimitsu Chuo Hospital,
Chiba (T. Iida); Kanagawa Cancer Center, Kanagawa (H.
Ito); Fujigaoka Hospital of Showa University, Kanagawa
(T. Suzuki); Hamamatsu University School of Medicine,
Shizuoka (K. Funai); Seirei Mikatahara General Hospital,
Shizuoka (M. Tanahashi); Nagoya University Graduate
School of Medicine, Aichi (K. Fukumoto); Aichi Cancer
Center Hospital, Aichi (S. Ito); Nagoya Daini Red Cross
Hospital, Aichi (H. Yoshioka); Nagoya City University
Graduate School of Medical Sciences, Aichi (M. Yano);
Aichi Medical University, Aichi (H. Numanami); Kariya
Toyota General Hospital, Aichi (T. Yamada); Graduate
School of Medicine, Gifu University, Gifu (H. Iwata); Na-
tional Mie Chuo Hospital, Mie (K. Adachi); Toyama Pre-
fectural Central Hospital, Toyama (H. Miyazawa);
Ishikawa Prefectural Central Hospital, Ishikawa (Y. Tsu-
nezuka); NHO Shiga Hospital, Shiga (S. Inoue); Takatsuki
Red Cross Hospital, Osaka (M. Suga); Osaka City Univer-
sity Hospital, Osaka (N. Nishiyama); Osaka University
Graduate School of Medicine, Osaka (Y. Shintani); Osaka
City General Hospital, Osaka (R. Yamamoto); Osaka
Medical Center for Cancer and Cardiovascular Diseases,
Osaka (J. Okami); Kishiwada City Hospital, Osaka (M.
Kawashima); Wakayama Medical Center Japanese Red
Cross Society, Wakayama (S. Sumitomo); Kobe City Med-
ical Center General Hospital, Hyogo (Y. Takahashi); Hy-
ogo Cancer Center, Hyogo (M. Yoshimura); Nishi-Kobe
Medical Center, Hyogo (Y. Otake); Tottori University
Hospital, Tottori (H. Nakamura); Okayama University
Graduate School of Medicine, Okayama (S. Miyoshi);
Kurashiki Central Hospital, Okayama (J. Nakano); Kawa-
saki Medical School, Okayama (M. Nakata); NHO Yama-
guchi Ube Medical Center, Yamaguchi (K. Sugi); Kagawa
Prefectural Central Hospital, Kagawa (T. Misao); Kochi
Health Sciences Center, Kochi (T. Okamoto); NHO Shi-
koku Cancer Center, Ehime (S. Sawada); Graduate School
of Medical Sciences Kyushu University, Fukuoka (T.
Yano); Kyushu Cancer Center, Fukuoka (K. Sugio); Ku-
mamoto Chuo Hospital, Kumamoto (T. Saishoji); Naga-
saki University Graduate School of Biomedical Sciences
Nagasaki (N. Yamasaki); Japanese Red Cross Nagasaki
Genbaku Hospital, Nagasaki (I. Sano); Sasebo City Gen-
eral Hospital, Nagasaki (A. Nakamura).
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TABLE E1. Univariable analysis for acute exacerbation
Factors Categories Numbers OR 95% CI P value
Age 1763 1.017 0.994-1.041 .141
Sex
Male 1593 1.000 — —
Female 170 0.332 0.145-0.763 .009
BMI
1746 0.980 0.930-1.031 .434
Smoking history
Never smoker 109 1.000 — —
Ex-smoker 1006 1.336 0.657-2.720 .424
Current smoker 632 0.893 0.424-1.879 .765
Brinkman index
1742 1.000 1.000-1.000 .413
Comorbidities
Asthma  1742 1.000 — —
þ 33 0.971 0.293-3.217 .962
Emphysema  1167 1.000 — —
þ 589 0.778 0.546-1.109 .165
Collagen disease  1654 1.000 — —
þ 102 0.936 0.463-1.892 .854
Neoadjuvant chemotherapy
 1686 1.000 — —
þ 73 1.207 0.569-2.562 .624
Neoadjuvant radiation
 1728 1.000 — —
þ 32 1.401 0.485-4.044 .533
WBC (/mL)
1737 1.000 1.000-1.000 .111
CRP (g/dL)
<2.0 1462 1.000 — —
>2.0 231 1.425 0.923-2.201 .110
LDH (IU/L)
1730 1.002 1.000-1.004 .064
KL-6 (U/mL)
<1000 834 1.000 — —
>1000 209 2.189 1.405-3.409 <.001
CEA (ng/mL)
1664 1.000 0.997-1.004 .883
PaO2 (torr)
1552 0.996 0.981-1.011 .609
PaCO2 (torr)
1547 0.954 0.914-0.995 .030
VC (L)
1750 0.566 0.441-0.728 <.001
%VC
<80 263 1.000 — —
>80 1478 0.588 0.395-0.873 .009
FEV1 (L)
1748 0.683 0.496-0.941 .020
FEV1%
<70 460 1.000 — —
>70 1289 1.500 1.003-2.243 .048
%FEV1
1742 0.995 0.987-1.002 .176
DLCO (mL/min/torr)
1121 0.957 0.916-0.999 .047
(Continued)
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TABLE E1. Continued
Factors Categories Numbers OR 95% CI P value
%DLCO
1128 0.997 0.989-1.006 .532
Radiologic findings
UIP pattern 1300 1.000 — —
Non-UIP pattern 463 0.603 0.400-0.909 .016
Pathologic findings
UIP pattern 709 1.000 — —
Non-UIP pattern 418 0.904 0.608-1.343 .616
No IP diagnosis 426 0.635 0.411-0.981 .041
History of AE
 1741 1.000 — —
þ 20 4.295 1.628-11.33 .003
Preoperative steroid use
 1651 1.000 — —
þ 103 2.522 1.504-4.231 <.001
pTNM stage
1a 547 1.000 — —
1b 481 1.349 0.858-2.120 .195
2a 70 1.488 0.638-3.474 .358
2b 241 1.832 1.101-3.049 .020
3a 244 2.022 1.230-3.323 .006
3b 114 1.011 0.459-2.229 .979
4 34 2.309 0.846-6.307 .103
Operation time (min)
1753 1.003 1.002-1.005 <.001
Bleeding (mL)
1744 1.001 1.000-1.001 <.001
Transfusion
 1629 1.000 — —
þ 124 2.276 1.392-3.723 .001
Surgical procedures
Wedge Resection 275 1.000 — —
Segmentectomy/lobectomy 1386 2.930 1.521-5.644 .001
Bilobectomy/pneumonectomy 94 5.032 2.175-11.64 <.001
Tumor location
Upper lobe 670 1.000 — —
Middle lobe 77 0.963 0.445-2.083 .924
Lower lobe 958 0.705 0.502-0.991 .044
Multiple 5 0.000 N/A
VATS
 964 1.000 — —
þ 798 1.199 0.869-1.654 .268
Node dissection
0 311 1.000 — —
1 339 2.979 1.559-5.694 .001
2 1104 2.587 1.436-4.661 .002
AE, Acute exacerbation; BMI, body mass index; CEA, carcinoembryonic antigen; CI, confidence interval; CRP, C-reactive protein; DLCO, diffusing capacity for carbon
monoxide; FEV1, forced expiratory volume in 1 second; IP, interstitial pneumonia; LDH, lactate dehydrogenase; OR, odds ratio; Paco2, partial pressure of carbon dioxide;
Pao2, partial pressure of oxygen;UIP, usual interstitial pneumonia; VATS, video-assisted thoracic surgery;VC, vital capacity;WBC,white blood cell;%VC, percent vital capacity;
FEV1%, percent forced expiratory volume in 1 second;%DLCO, percent predicted diffusing capacity for carbon monoxide.
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